

EQA round: VVV2/23 - Maternal Diagnostic Screening (Triple Test)

Deadline: 3.11.2023

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(238) free β-hCG	[U/L]				9							9	8	89
Sample A1		40,9	3,8	9,4	9							9	8	89
(60) Roche		40,1	5	12	8	0	CVPG	43,1	1,3	15%	36,6	49,6	8	
Other					1	0							1	
							1x 24							
Sample B1		46,9	3,2	6,7	9							9	9	100
(60) Roche		46,5	3,8	8,1	8	0	CVPG	48	1,2	15%	40,8	55,2	8	
Other					1	0							1	
							1x 24							
(239) PAPP-A	[U/L]				12							12	10	83
Sample A1		0,292	0,037	13	12							12	10	83
(60) Roche		0,293	0,043	15	10	0	CVPG	0,305	0,011	15%	0,259	0,351	10	
Other					2	0							2	
							2x 24							
Sample B1		1,33	0,081	6	12							12	12	100
(60) Roche		1,34	0,078	5,9	10	0	CVPG	1,36	0,032	15%	1,15	1,57	10	
Other					2	0							2	
							2x 24							
Set 2														
(370) AFP	[μg/L]				13							10	10	100
Sample A2		7,76	0,85	11	13							10	10	100
(60) Roche		8,37	0,5	5,9	6	0	CVPG	8,53	0,37	20%	6,82	10,3	6	
Other					7	0							4	
							1x 1, 4x 12, 1x 162, 1x 179							
Sample B2		59,5	7	12	13							10	10	100
(60) Roche		65,1	3,6	5,6	6	0	CVPG	66,2	3	20%	52,9	79,5	6	
Other					7	0							4	
							1x 1, 4x 12, 1x 162, 1x 179							
(373) hCG	[kU/L]				13							9	8	89
Sample A2		114	34	30	13							9	9	100
(60) Roche		101	11	10	6	0	CVPG	105	6,8	18%	86,1	124	6	
Other					7	0							3	
							1x 1, 3x 12, 1x 29, 1x 36, 1x 179							
Sample B2		48,8	14	28	13							9	8	89
(60) Roche		41,9	4,8	11	6	0	CVPG	43,7	3	18%	35,8	51,6	6	
Other					7	0							3	
							1x 1, 3x 12, 1x 29, 1x 36, 1x 179							
(375) Estriol unconjug.	[nmol/L]				13							13	13	100
Sample A2		0,4	0,24	60	13							13	13	100
(12) Beckman Coulter		0,64	0,074	12	5	0	CVPG	0,624	0,056	33%	0,418	0,83	5	
(29) Siemens (Immulin)		0,242	0,002	0,91	8	0	CVPG	0,241	0,001	33%	0,161	0,321	8	
Sample B2		2,54	1,3	52	13							13	13	100
(12) Beckman Coulter		3,9	0,14	3,6	5	0	CVPG	3,84	0,18	33%	2,57	5,11	5	
(29) Siemens (Immulin)		1,74	0,3	18	8	0	CVPG	1,68	0,15	33%	1,12	2,24	8	
1. trimester														
(240) free β-hCG (MoM)	[MoM]				7							7	7	100
Mother X1		1,11	0,12	11	7							7	7	100
(60) Roche		1,11	0,11	10	6	0	CVPG	1,25	0,075	33%	0,837	1,67	6	
Other					1	0							1	
							1x 24							
Mother Y1		0,93	0,03	3,2	7							7	7	100
(60) Roche		0,935	0,022	2,4	6	0	CVPG	1	0,045	33%	0,67	1,33	6	
Other					1	0							1	
							1x 24							
(241) PAPP-A (MoM)	[MoM]				11							11	10	91
Mother X1		0,082	0,018	22	11							11	10	91
(60) Roche		0,085	0,022	26	9	0	CVPG	0,085	0,005	33%	0,056	0,114	9	
Other					2	0							2	
							2x 24							
Mother Y1		0,726	0,1	14	11							11	11	100
(60) Roche		0,725	0,096	13	9	0	CVPG	0,716	0,041	33%	0,479	0,953	9	

EQA round: VVV2/23 - Maternal Diagnostic Screening (Triple Test)

Deadline: 3.11.2023

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Other					2	0	2x 24					2		
2. trimester														
(380) AFP (MoM)	[MoM]				13							10	9	90
Mother X2		0,196	0,014	7,1	13							10	9	90
(60) Roche		0,205	0,007	3,6	6	0	CVPG	0,198	0,01	23%	0,152	0,244	6	
Other					7	0						4		
							1x 1, 4x 12, 1x 162, 1x 179							
Mother Y2		1,67	0,13	7,6	13							10	9	90
(60) Roche		1,77	0,16	8,8	6	0	CVPG	1,73	0,11	23%	1,33	2,13	6	
Other					7	0						4		
							1x 1, 4x 12, 1x 162, 1x 179							
(382) hCG (MoM)	[MoM]				13							9	9	100
Mother X2		4,08	0,77	19	13							9	9	100
(60) Roche		3,75	0,64	17	6	0	CVPG	4,18	0,52	40%	2,5	5,86	6	
Other					7	0						3		
							1x 1, 3x 12, 1x 29, 1x 36, 1x 179							
Mother Y2		1,47	0,23	16	13							9	9	100
(60) Roche		1,36	0,22	16	6	0	CVPG	1,51	0,21	40%	0,906	2,12	6	
Other					7	0						3		
							1x 1, 3x 12, 1x 29, 1x 36, 1x 179							
(384) Estriol unconjug. (MoM)	[MoM]				13							13	12	92
Mother X2		0,135	0,022	16	13							13	12	92
(12) Beckman Coulter		0,155	0,022	14	5	0	CVPG	0,161	0,017	40%	0,096	0,226	5	
(29) Siemens (Immulite)		0,12	0,015	12	8	0	CVPG	0,121	0,01	40%	0,072	0,17	8	
Mother Y2		1,13	0,21	18	13							13	12	92
(12) Beckman Coulter		1,17	0,052	4,5	5	0	CVPG	1,22	0,11	40%	0,732	1,71	5	
(29) Siemens (Immulite)		1,09	0,16	15	8	0	CVPG	1,06	0,13	40%	0,636	1,49	8	